Trials
2 active
4 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “(Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).”In the company’s words, NCT05607004 on ClinicalTrials.gov
- Tested for
- Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Precocious Puberty, Gonadotropin-dependent
- Main trialPhase 2
- “This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part. The PK part (how the body processes the drug) will enroll about 18 participants. All participants will take (Z)-endoxifen capsules daily. Twelve participants will be randomly assigned (50/50 chance) to take (Z)-endoxifen alone or…”In the company’s words, NCT05607004 on ClinicalTrials.gov
- Other names
- Topical endoxifen
Other drugs for Breast Neoplasms
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up2
- NovPhase 2 trial completes · ClinicalTrials.gov
- Jun 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Nov 2026 | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | |
| Phase 2Not yet recruiting | Jun 2028 | (Z)-Endoxifen in Girls With MAS-Associated Peripheral Precocious Puberty | |
| Phase 2Completed | 10 Sep 2018 | Topical Endoxifen in Women | |
| Phase 2Completed | 14 Jun 2024 | Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026